The analysis of cell free circulating (cfc) DNA and RNA nanoparticulate biomarkers continues to become more widely used for cancer diagnostics and management. Generally, cfc-DNA for “liquid biopsies” is isolated form plasma using relatively long and involved processes which are not suitable for point of care (POC) diagnostics. We have now demonstrated a dielectrophoretic (DEP) based approach that allows cfc-DNA and RNA nanoparticulate biomarkers from chronic lymphocytic leukemia (CLL) patients to be isolated in about 10 minutes directly from a small volume (25ul) of patient whole blood and plasma. Cfc-DNA isolated from fifteen CLL patient blood samples and eleven CLL patient plasma samples were PCR amplified to identify the VHL genotype and then sequenced. The DNA sequencing results for ccf-DNA isolated by DEP were comparable to two gold standard methods for CLL analysis. The new DEP technology and devices set the stage for “seamless sample to answer” diagnostic systems which will allow a variety of important cancer and other disease biomarkers to be rapidly isolated and analyzed directly from whole blood and other clinical samples.
Journal: TechConnect Briefs
Volume: 3, Biotech, Biomaterials and Biomedical: TechConnect Briefs 2015
Published: June 14, 2015
Pages: 71 - 74
Industry sectors: Advanced Materials & Manufacturing | Medical & Biotech
Topicss: Biomaterials, Cancer Nanotechnology